Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05745207
Status:
COMPLETED
Last Update Posted:
2024-04-19
First Post:
2023-02-16
Brief Title:
A Study To Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A First-In-Human Two-Part Randomized Double-Blind Placebo-Controlled Single-Ascending Dose Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of E2086 in Healthy Adult and Elderly Subjects
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None